Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review

Conclusion: Several reports have described the management and occurrence of severe thrombocytopenia after immune checkpoint inhibitor administration in patients with different neoplasms. Physicians should be alert to the potential of rare irAEs, such as severe thrombocytopenia.

Source: In Vivo - February 27, 2020 Category: Research Authors: MOURI, A., KAIRA, K., SHIONO, A., MIURA, Y., KAGAMU, H. Tags: Clinical Studies Source Type: research